Last Week Clinigen Group Plc (LON:CLIN) Ratings

Clinigen Group Plc (LON:CLIN) Corporate Logo

Clinigen Group Plc (LON:CLIN) Ratings Coverage

In total 4 analysts cover Clinigen Group (LON:CLIN). “Buy” rating has 4, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 14 are the (LON:CLIN)’s analyst reports since July 3, 2018 according to StockzIntelligence Inc. On Wednesday, October 3 the rating was maintained by Peel Hunt with “Buy”. On Tuesday, July 17 Numis Securities maintained Clinigen Group Plc (LON:CLIN) with “Buy” rating. On Tuesday, September 4 the stock of Clinigen Group Plc (LON:CLIN) earned “Buy” rating by Peel Hunt. The stock rating was maintained by UBS with “Buy” on Thursday, September 27. On Thursday, November 1 the firm has “Buy” rating by Peel Hunt given. On Tuesday, July 3 the rating was maintained by Peel Hunt with “Buy”. The company rating was maintained by Peel Hunt on Wednesday, August 1. On Wednesday, July 25 Peel Hunt maintained the shares of CLIN in report with “Buy” rating. On Tuesday, October 9 the firm has “Buy” rating given by Peel Hunt. On Thursday, September 27 the rating was maintained by Peel Hunt with “Buy”. Listed here are Clinigen Group Plc (LON:CLIN) PTs and latest ratings.

01/11/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 1300.00 Maintain
15/10/2018 Broker: RBC Capital Markets Rating: Top Pick Old Target: GBX 1360.00 New Target: GBX 1470.00 Unchanged
09/10/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 1350.00 New Target: GBX 1300.00 Maintain
08/10/2018 Broker: Numis Securities Rating: Buy Old Target: GBX 1275.00 New Target: GBX 1275.00 Maintain
03/10/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 1350.00 Maintain
27/09/2018 Broker: UBS Rating: Buy Old Target: GBX 1160.00 New Target: GBX 1160.00 Maintain
27/09/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 1350.00 Maintain
04/09/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 1350.00 Maintain
01/08/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 1350.00 Maintain
25/07/2018 Broker: Numis Securities Rating: Buy Old Target: GBX 1208.00 Maintain

The stock increased 0.68% or GBX 5.5 during the last trading session, hitting GBX 816.5.Clinigen Group Plc has volume of 243,961 shares. Since December 8, 2017 CLIN has 0.00% and is . CLIN underperformed the S&P 500 by 15.62%.

Clinigen Group plc operates as a specialty pharmaceutical and services firm in the United Kingdom, Europe, the United States, and internationally.The firm is valued at 1.08 billion GBP. The Company’s Clinigen Clinical Trial Services business supplies and manages commercial medical products, including comparator drugs, adjuvant drugs, and rescue therapies for patients in clinical trials, as well as provides value added services.The P/E ratio is 36.29. The companyÂ’s Idis Managed Access business is involved in the consultancy, development, management, and implementation of managed access programs for biotechnology and pharmaceutical companies.

For more Clinigen Group Plc (LON:CLIN) news posted recently go to: Nature.com, Prnewswire.com, Prnewswire.com, Prnewswire.com or Nature.com. The titles are as follows: “Hypoxia and metabolic adaptation of cancer cells – Nature.com” posted on January 25, 2016, “Indivior Announces NDA Acceptance of RBP-7000 Risperidone Monthly Depot – PR Newswire” on December 12, 2017, “AstraZeneca Provides Update On Phase III Trial Of Selumetinib In Non-Small Cell Lung Cancer – PR Newswire” with a publish date: August 09, 2016, “FDA Approves SUBLOCADEâ„¢ (Buprenorphine Extended-Release), the First and Only Once-Monthly Injectable Buprenorphine Formulation to Treat Moderate to Severe Opioid Use Disorder – PR Newswire” and the last “A simple and predictive phenotypic High Content Imaging assay for Plasmodium falciparum mature gametocytes to identify malaria transmission blocking compounds – Nature.com” with publication date: November 10, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.